!

Benchmark Botanics Appoints Hon. James Moore To Board of Directors

VANCOUVER, British Columbia – April 17, 2019 /Canna Newswire/ – Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (“Benchmark” or the “Company”) is pleased to announce the appointment of Hon. James Moore to the Board of Directors. The appointment strongly positions the company to continue with its business plan and to develop its operations and cannabis assets.

“We are pleased to welcome James to the Benchmark family as a member of our Board of Directors,” said William Ying, CEO of Benchmark Botanics. “James brings a wealth of global experience across a broad base of industry sectors and the political arena. Benchmark will greatly benefit from his professional knowledge, experience and strategic guidance.”

James Moore is a senior business advisor at the multinational law firm Dentons, and a public policy advisor at the global firm Edelman. He also serves as Chancellor of the University of British Columbia, is the national vice-chair of the Canadian Cancer Society, a member of the NAFTA Council for the Government of Canada and a corporate director. Previously he served as Canada’s Minister of Industry, Minister of Canadian Heritage & Official Languages and Secretary of State for the Asia Pacific Gateway and Minister for the 2010 Olympics over a 15-year career as a Member of Parliament.

As cannabis regulatory reform continues to unfold across the globe and domestic and international opportunities emerge in its wake, Benchmark Botanics’ qualified Board of Directors and management team are expected to position the Company to take full advantage of these opportunities and continue to add to its diversified portfolio of cannabis industry products and investments.

About Benchmark Botanics Inc.
Benchmark Botanics is a diversified multi-licensed cannabis producer focused on its three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company’s business plan includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia. Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

# CNW #

Investor Relations:
Benchmark Botanics, Inc.
Email: info@bbtinc.ca
Tel: 604-238-0005
www.benchmarkbotanics.com

Media Contact:
David Joseph
David Joseph Marketing
davidjosephmarketing@telus.net
+1 604-619-9192

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

   

CBD
1
Respected Neurosurgeon Brings Distinguished Career and Medical Expertise to Geocann’s Executive Management Team

Anthony Petraglia MD joins Geocann as Chief Medical Officer and will serve as Chairman of the company’s Scientific and Medical Advisory Board

MANUFACTURING
1
Geocann Announces Proven Stability Data Ensuring Desired Levels of Active Ingredients Are Maintained Throughout Promised Shelf-Life

While many cannabinoid products fall short of label claims, Geocann’s data confirms the VESIsorb® delivery system maintains key cannabinoids and terpenes

CBD
1
Ignite International Brands Signs Definitive Agreement with Taylor Mammon & Nathan Limited for Manufacture and Distribution of CBD Products in Europe

Taylor Mammon gains exclusive license to manufacture, package and distribute a wide array of premium Ignite-branded CBD products in the United Kingdom